- PROFESSOR | Medicine, Cardiology
Juan Jose Badimon, PhD, is Professor of Medicine and Director of the Atherothrombosis Research Unit at the Cardiovascular Institute, The Mount Sinai School of Medicine, New York. Dr. Badimon was born in Barcelona, Spain. He graduated from the University of Barcelona in 1982. In the same year, he moved to the United States where he served as Post-doctoral research Fellow at Mayo Clinic until 1984. Then he moved on to Mount Sinai New York (1984 -1990), Massachusetts General Hospital, Boston (1990-1994). In 1994 he returned to Mount Sinai School of Medicine in New York.
Among Honors awards received; he is a fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA). He was awarded a Doctor Honoris Causa by the Catholic University of Buenos Aires, Visiting Professor Ad-Honorem of the Central University of Bogota, Colombia; Honorary Professorship of the Tucuman School of Medicine, Argentina; Honorary Memberships of the Spanish and Venezuelan Society of Arteriosclerosis, as well as the Societies of Cardiology of Chile, Argentina and Mexico.
Dr. Badimon's group research interests are focused on pathogenesis and treatment of atherothrombosis in general. More specifically, his lab is interested on the role of lipids and HDL in the genesis and progression of atherosclerotic lesions as well as the clinical manifestations of atherothrombosis. On this regard, he has worked on the role played by the vulnerable plaque and vulnerable blood to define the vulnerable or high-risk patient. Within this line of research he is involved in the optimization of the use of antithrombotic agent to reduce the thrombotic implications of atherothrombosis and in the development of more potent and efficient new antithrombotic agents. The role of the tissue factor pathway in atherothrombosis, as well as the potential therapeutic implications of its inhibition, is one of his lab major interests. His lab has been very instrumental in studying the activities and optimizing the therapeutic doses of some of the most recent inhibitors of the Tissue Factor pathway (thrombin inhibitors, anti FXa and/or anti FVIIa). More recently he has been involved in the use of non-invasive imaging modalities (MRI and CT) for detecting early atherosclerotic lesions as well as monitoring the effectiveness of therapeutic approaches in arteriosclerosis and thrombosis.The non-invasive imaging modalities are also a major asset in the on-going studies on the pathogenesis of left ventricular remodeling post-ichemia/reperdusion. We are now interested in a better knowledge of the molecular pathway involved in the LV remodeling as well as indentification and development of therapeutic strategies.
He has trained more than 30 fellows from different countries throughout his career. The majority of these fellows after their stage with him have achieved seniors and independent positions in their new appointments. Dr. Badimon has published more than 230 peer-reviewed articles in atherothrombosis, imaging and cardiovascular diseases in general. He serves as reviewer for more than 10 top journals in cardiovascular diseases.
Honors• Member of Honor of the Spanish Royal Academy of Pharmacy. • Doctor Honoris Causa by the Catholic University of Buenos Aires,. • Fellow of the American College of Cardiology (FACC). • Fellow of the American Heart Association (FAHA). • Visiting Professor Ad-Honorem at the Central University of Bogota, Colombia; • Honorary Professorship of the Tucuman School of Medicine, Argentina. Honorary Memberships - Societies of Cardiology Societies of Spain, Argentina, Chile, Colombia, Mexico, Paraguay, Peru. - Societies of Arteriosclerosis of Spain, Venezuela and Ecuador,and Argentinian Society of Lipids Major Committee Assingments Reviewer for Grants NIH Sections of NHLBI, Thrombosis and AIDS, Reviewer for AHA and NY Academy of Sciences Reviewer for Grants and Application the Commission Interministerial de Ciencia y Tecnologia (Grant Reviewing Agency of Spain) Reviewer for Grants from the Veterans Administration Committee Assignments in Professional Societies: Member of the Scientific Board of the Spanish Familia Hypercholesterolemia Foundation. International Society of Thrombosis and Hemostasis Arteriosclerosis Council American Heart Association Thrombosis Council American Heart Association. American College of Cardiology Spanish Society of Arteriosclerosis The New York Academy of Science Chairman of the Vessel Wall-Blood Interaction Committee Vulnerable Plaque.Org Editorial Boards Journal of the American College of Cardiology Journal of Thrombosis and Haemostasis Current Cardiology Review Revista Española de Cardiologia Cardiovascular Drugs and Therapy Kardiology Frequent reviewer for Journal of the American College of Cardiology New England Journal of Medicine JAMA Circulation Research Circulation Journal of Clinical Investigation Archives of Intenal Medicine European Heart Journal Atherosclerosis Atherosclerosis, Thrombosis and Vascular Biology Journal of the American Heart Association Journal of Cardiovascular Pharmacology Thrombosis Research among others cardiovascular journals
Licenciature in Pharmacy, University of Barcelona
PhD Summa Cum Laude, University of Barcelona
Specialty in Pharmacology, University of Barcelona and CSIC
EnglishDownload the CV
Simon Dack Award
The American College of Cardiology
Recipient of the John Paul II Medal
Jagiellonian University of Krakow
Researcher of the 2004 Year
The Royal Academic of Pharmacy of Spain
Xth Joan D'Alos Award
VII Intern Award
Association Thrombosis and Haemostasis
Dr. Herman and Suzanne Denber Award for Cardiovascular Research
The Mount Sinai Medical Center
- Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution MRI. - Open Label Study Adult Subjects Investigating the Antithrombotic Effects of the New Reversible P2Y12 Inhibitor BR-5224 versus Placebo using an Ex Vivo Model of Thrombosis. - Antithrombotic Effects of 3 Novel Dual Flla/FXa Inhibitors versus Flla-Inhibition and FXa Inhibition Alone: An Open Label Ex Study in Healthy Volunteers. - An Open-Label Study to Assess the antithrombotic Effects of BMS-561389 in an Experimental Ex Vivo perfusion system. - A Phase-1, Open-Label Study in Healthy Adult Male and Female Subjects to Assess the antithrombotic Effect Following a Single Dose of DU-176b, an Oral Direct Factor Xa Inhibitor, Using an Ex Vivo Human Model of Thrombosis. - A Phase-1, Randomize, Assessor-Blinde, Four-treatment, Three-Period,Incomplete Block Crossover Study in Healthy Adult Male and Female Subjects to Assess the Antithrombotic Effect of Single Oral Doses Of DZ-697b Compared to Clopidrogrel Using a Ex Vivo Human Model of Thrombosis. - An Open-Label,Pilot Study in Healthy Adult Subjects to Assess the Antithrombotic Effects of Two Doses of LA-149,A Novel NO-Donor, versus Abcixmab. - A Pharmacodynamic Comparison of Prasugrel versus High Dose Clopidogrel in Subjects with T2DM and CVD. -Restoration of Platelet Function Following a Loading Dose of Prasugrel an Study Utilizing Homologous Platelet Supplementation. - Double-Blind, Crossover, Randomized Study to Assess the Antithrombotic Effect of Clopidrogel (75mg) with Aspirin (75mg) In Comparison with Clopidogrel (75mg) Alone and Aspirin (75mg) Alone After Repeated Administration in Healthy Volunteers. - Effect of Platelet Concentrates on the PLatelet Reactivity of Subjects on Clopidrogel and Aspirin Treatments. - Effects of Treatments with Angiotensin-II Receptor Blocker Candesartan on Ex Vivo Thrombus Formation in CAD Patients. - An in Vitro Study to Investigate the Effects on Dronedarone on Platelet Reactivity of Coronary Artery Disease Patients. - Case-Control Study to Compare the Platelet Reactivity of Depressed versus Non-depressed Patients with Coronary Artery Diseases- Translational Studies of Depression, Platelets and CAD. - Randomized Controlled Trial to Compare the in vivo Effects of SSRIs, 5-HT2A Receptor Antagonist and Cognitive Behavioral Therapy (CBT) On Platelet Reactivity, Thrombosis and Platelet 5-HT2A Receptor Density In Depressed CAD Patients. - Randomized, Crossover Study of the Antithrombotic Effects of Ticagrelor + Aspirin versus Clopidogrel + Aspirin when Administered with Bivalirudin. (NCT01642238) - Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type-2 Diabetic Patients. (NCT01823510) - Reversing Ticagrelor's Antithrombotic Effects With Fresh Platelets.(NCT02201394)
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Badimon during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Boehringer Ingelheim Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.